Stockreport

Cartesian Therapeutics Highlights Recent Progress and Outlines 2026 Outlook

Cartesian Therapeutics, Inc.  (RNAC) 
PDF Enrollment on track in Phase 3 AURORA trial of Descartes-08 in myasthenia gravis  IND application for Descartes-08 in myositis accepted by FDA; seamless adaptive clinic [Read more]